Hydralazine was the most common drug for others to be evaluated against .
Diazoxide , given as 75 mg bolus injections , appears to be associated with maternal hypotension requiring treatment , and ketanserin is less effective than hydralazine at reducing blood pressure .
There is no other clear evidence that any one of the other antihypertensive agents is better than another for women with severe hypertension during pregnancy .
Exceptions are diazoxide and ketanserin , which are probably not good choices
BACKGROUND Very high blood pressure during pregnancy poses a serious threat to women and their babies .
The use of drugs to lower blood pressure will reduce this risk for the women , and possibly also for the baby .
OBJECTIVES The objective of this review was to compare different antihypertensive drugs used for treatment of severe hypertension during pregnancy .
Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study.
The prospect i ve feasibility study was design ed to determine whether treatment with antithrombin ( AT ) concentrates could be used for patients with severe preeclampsia to provide clinical efficacy without the full systemic antihypertensive drug . Twenty-nine severe preeclamptic patients ( 24 to 36 weeks of gestation , gestosis index [ GI ] > /= 6 points ) were r and omized to receive AT ( 1500 U/day ) or not . AT was given intravenously once daily for 7 consecutive days . Twenty-four hours of continuous infusion of 5000 U/day of unfractionated heparin was given simultaneously in both groups . There were no statistical differences in the clinical profiles of the two groups . Maternal symptoms were evaluated from the difference of GI before and after treatment , and fetal findings were evaluated from the changes of the biophysical profile score . Improvement was significantly greater in the AT group for both the GI ( P = 0.046 ) and the biophysical profile score ( P = 0.022 ) . The improvement of coagulation parameters was also evaluated . The improvement of plasmin-plasmin inhibitor complex ( PPIC ) , D-dimer levels , and platelet counts was observed in the AT group compared with the non-AT group . The coagulation index as a composite coagulation test parameter showed a significantly improvement in the AT group . No adverse events related to AT were observed . Given that AT plus heparin was significantly better than treatment with heparin alone for improvement of both GI and biophysical profile of infant , it is suggested that therapy with AT alone might be effective enough for severe preeclampsia
Hydralazine was the most common drug for others to be evaluated against .
Diazoxide , given as 75 mg bolus injections , appears to be associated with maternal hypotension requiring treatment , and ketanserin is less effective than hydralazine at reducing blood pressure .
There is no other clear evidence that any one of the other antihypertensive agents is better than another for women with severe hypertension during pregnancy .
Exceptions are diazoxide and ketanserin , which are probably not good choices
BACKGROUND Very high blood pressure during pregnancy poses a serious threat to women and their babies .
The use of drugs to lower blood pressure will reduce this risk for the women , and possibly also for the baby .
OBJECTIVES The objective of this review was to compare different antihypertensive drugs used for treatment of severe hypertension during pregnancy .